-
A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease
NCT06587828 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Texas: Bellaire
-
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
NCT06433752 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Texas: Austin, Dallas, Edinburg, Frisco
-
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
NCT07067463 ·
Phase: Phase 3 ·
Ages: 18 Years to 60 Years ·
Sex: All (male and female)
· Texas: San Antonio, Sherman
-
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
NCT07299019 ·
Phase: Phase 3 ·
Ages: 18 Years to 60 Years ·
Sex: All (male and female)
· Texas: San Antonio, Sherman
-
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
NCT07225504 ·
Phase: Phase 3 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Texas: Dallas, Plano
-
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
NCT06782490 ·
Phase: Phase 2 ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female)
· Texas: Lewisville
-
A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years
NCT06735248 ·
Phase: Phase 2 ·
Ages: 18 Years to 55 Years ·
Sex: All (male and female)
· Texas: Dallas, El Paso, Plano
-
AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy
NCT06063850 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female)
· Texas: Austin
-
AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis
NCT06665165 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Texas: Houston
-
An Online Nurse-Led Purpose-Focused Group Program for Adult Women With Multiple Sclerosis: Effects on Meaning and Quality of Life
NCT07555015 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: Female
· Texas: Denton
-
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
NCT04047628 ·
Phase: Phase 3 ·
Ages: 18 Years to 55 Years ·
Sex: All (male and female)
· Texas: Dallas, Houston
-
Care in Multiple Sclerosis (MS)
NCT07011914 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Texas: Houston
-
Delivery of a Culturally Tailored Exercise Training Intervention for Hispanics With Multiple Sclerosis
NCT07606742 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Texas: Houston
-
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
NCT06846281 ·
Phase: Phase 3 ·
Ages: 40 Years to 70 Years ·
Sex: All (male and female)
· Texas: Austin, Dallas, Fort Worth, Plano
-
Multiple Sclerosis Implementation Network (Registry)
NCT07415824 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Texas: Austin, Houston
-
Music-4-MS to Improve Cognition in People Living With Multiple Sclerosis: A Feasibility Study
NCT07759115 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years to 80 Years ·
Sex: All (male and female)
· Texas: Austin
-
NARCOMS Registry: A Multiple Sclerosis Registry
NCT01018537 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Texas: Dallas
-
Neuromodulating Cortical Regions Involved in Neurogenic Bladder in MS
NCT06072703 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: Female
· Texas: Houston
-
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
NCT07325292 ·
Phase: Phase 3 ·
Ages: 18 Years to 60 Years ·
Sex: All (male and female)
· Texas: El Paso, Plano
-
Non-invasive BCI-controlled Assistive Devices
NCT05183152 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years to 80 Years ·
Sex: All (male and female)
· Texas: Austin
-
Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis
NCT05285891 ·
Phase: Phase 4 ·
Ages: 18 Years to 55 Years ·
Sex: All (male and female)
· Texas: Dallas, Houston
-
Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research
NCT07623668 ·
Phase: Phase 3 ·
Ages: 18 Years to 50 Years ·
Sex: All (male and female)
· Texas: Dallas, Houston
-
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
NCT07002034 ·
Phase: Phase 2 ·
Ages: 18 Years to 80 Years ·
Sex: All (male and female)
· Texas: Austin
-
Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study
NCT05104983 ·
Phase: Phase 2 ·
Ages: 1 Day to 6 Months ·
Sex: All (male and female)
· Texas: Houston
-
Study of COYA 302 for the Treatment of ALS
NCT07161999 ·
Phase: Phase 2, Phase 3 ·
Ages: 18 Years to 80 Years ·
Sex: All (male and female)
· Texas: Austin, Dallas, Houston, San Antonio
-
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
NCT05877963 ·
Phase: Phase 3 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Texas: Houston
-
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
NCT06408259 ·
Phase: Phase 3 ·
Ages: 10 Years to 17 Years ·
Sex: All (male and female)
· Texas: El Paso
-
TSC Biosample Repository and Natural History Database
NCT05676099 ·
Phase: Not specified ·
Ages: No age limits stated ·
Sex: All (male and female)
· Texas: Dallas, Houston
-
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
NCT03816345 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Texas: Dallas, Fort Worth, Houston, Richardson
-
The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study
NCT06796504 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 22 Years to 60 Years ·
Sex: All (male and female)
· Texas: Austin, Houston
-
Treatment of Cognitive Deficits in Multiple Sclerosis With High-Definition Transcranial Direct Current Stimulation
NCT05958381 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Texas: Richardson